January 24, 2014
Takeda Pharmaceutical and the Danish-based H. Lundbeck A/S jointly announced on January 22 that they have started sales of the major depressive disorder (MDD) treatment Brintellix (vortioxetine hydrobromide) in the US. Brintellix is a novel antidepressant discovered by Lundbeck. The...read more